LMAO - LMAO STOCK NEWS

LMF Acquisition Opportunities (NASDAQ: LMAO) announced that its stockholders voted to approve the business combination with SeaStar Medical, with over 96% of votes in favor during a special meeting on October 18, 2022. Approximately 79% of issued shares were voted. The transaction is expected to close once all conditions are met, leading to LMAO's rebranding as SeaStar Medical Holding Corporation. Post-transaction, common stock and warrants will trade under new ticker symbols 'ICU' and 'ICUCW' on Nasdaq.

LMF Acquisition Opportunities (LMAO) has announced that its registration statement regarding the business combination with SeaStar Medical has been declared effective by the SEC. Stockholders are urged to vote on the proposals before the special meeting scheduled for October 18, 2022. If approved, the merger will close and trading under new ticker symbols will begin shortly thereafter. The board unanimously recommends voting in favor of the proposals, indicating strong support for the transaction.

SeaStar Medical has appointed Dr. Sai Prasad N. Iyer as Vice President of Medical Affairs and Clinical Development, effective September 15, 2022. Dr. Iyer, with 20 years of experience, will lead the upcoming pivotal clinical trial of the Selective Cytopheretic Device (SCD) aimed at treating acute kidney injury (AKI). This device is designed to mitigate hyperinflammation during continuous renal replacement therapy. SeaStar Medical, in a recent business combination with LMF Acquisition Opportunities (NASDAQ: LMAO), aims to enhance its public listing and market presence.

SeaStar Medical and LMF Acquisition Opportunities announced a successful case report of the Selective Cytopheretic Device (SCD) used in a 22-month-old patient with hemophagocytic lymphohistiocytosis (HLH). The patient, who showed signs of acute kidney injury, was treated with SCD therapy for four days, leading to stabilized sepsis and inflammation markers. Subsequently, a successful bone marrow stem cell transplant was conducted. The SCD aims to mitigate hyperinflammation and organ failure without causing immunosuppression. The device is currently under FDA review for pediatric use.

LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) announced an extension of its deadline to finalize a business combination with SeaStar Medical, Inc. from July 29, 2022, to October 29, 2022. This extension, permitted under the company’s charter, is supported by a $1,035,000 deposit into LMAO's trust account from its sponsor, LMFAO Sponsor, LLC. The additional time aims to facilitate the merger with SeaStar Medical, which is focusing on innovative extracorporeal therapies to combat hyperinflammation in critically ill patients.

SeaStar Medical has submitted a Humanitarian Device Exemption (HDE) application to the FDA for its Selective Cytopheretic Device (SCD), aimed at treating critically-ill children with acute kidney injury (AKI). The application is based on successful pilot studies showing the device's safety and probable clinical benefits for pediatric patients. Approximately 4,000 children in the U.S. suffer from AKI annually, with a mortality rate of around 50%. The acceptance of the application marks a significant advancement for pediatric specialists in managing AKI.

SeaStar Medical and LMF Acquisition Opportunities announce the publication of results from the SCD 005 clinical study in the Critical Care Explorations journal. The study met primary endpoints, demonstrating the Selective Cytopheretic Device (SCD) significantly reduced 60-day mortality rates from 81% in controls to 50% in treated patients, and down to 31% with extended treatment. The SCD showed a favorable safety profile with no serious adverse events. These findings support future studies that could lead to the SCD's broader application in treating inflammatory conditions.

SeaStar Medical Inc. announced the appointment of Dr. Kevin Chung as Chief Medical Officer, effective July 1, 2022. Dr. Chung brings over 20 years of experience in critical care and extracorporeal therapies, including significant contributions at military medical facilities. His leadership is expected to enhance SeaStar Medical’s clinical development, particularly its Selective Cytopheretic Device for managing hyperinflammation. This move coincides with SeaStar's planned merger with LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO), aiming for a public listing on Nasdaq, pending stockholder approval.

SeaStar Medical's Selective Cytopheretic Device (SCD) has received Breakthrough Device Designation from the FDA, facilitating accelerated review for a clinical trial targeting acute kidney injury (AKI) in adults. The SCD aims to combat hyperinflammation by selectively targeting neutrophils and monocytes, reducing mortality and dialysis dependency. SeaStar anticipates a vast U.S. market potential of $5.4 to $24 billion annually due to the economic burden of AKI. The FDA designation is expected to expedite regulatory processes ahead of the pivotal trial.